Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer.
Masashi TsunematsuTadashi UwagawaShinji OndaYoshihiro ShiraiNorimitsu OkuiMichinori MatsumotoKenei FurukawaKoichiro HarukiShunta IshizakiToru IkegamiPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2023)
CAR can be a predictor of non-response to anamorelin in patients with advanced pancreatic cancer, suggesting the importance of a comprehensive assessment of the inflammatory status.
Keyphrases